Randomized phase 2 study of FcRn antagonist efgartigimod in generalized myasthenia gravis

OBJECTIVE: To investigate safety and explore efficacy of efgartigimod (ARGX-113), an anti-neonatal Fc receptor immunoglobulin G1 Fc fragment, in patients with generalized myasthenia gravis (gMG) with a history of anti-acetylcholine receptor (AChR) autoantibodies, who were on stable standard-of-care...

Disgrifiad llawn

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Cyhoeddwyd yn:Neurology
Prif Awduron: Howard, James F., Bril, Vera, Burns, Ted M., Mantegazza, Renato, Bilinska, Malgorzata, Szczudlik, Andrzej, Beydoun, Said, Garrido, Francisco Javier Rodriguez De Rivera, Piehl, Fredrik, Rottoli, Mariarosa, Van Damme, Philip, Vu, Tuan, Evoli, Amelia, Freimer, Miriam, Mozaffar, Tahseen, Ward, E. Sally, Dreier, Torsten, Ulrichts, Peter, Verschueren, Katrien, Guglietta, Antonio, de Haard, Hans, Leupin, Nicolas, Verschuuren, Jan J.G.M.
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: Lippincott Williams & Wilkins 2019
Pynciau:
Article
Mynediad Ar-lein:https://ncbi.nlm.nih.gov/pmc/articles/PMC6556100/
https://ncbi.nlm.nih.gov/pubmed/31118245
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1212/WNL.0000000000007600
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg